Philip J Mease

Updating the OMERACT Filter: Core Areas as a Basis for Defining Core Outcome Sets

Francis Guillemin, Laure Gossec, Maxime Dougados, 2014, The Journal of Rheumatology.

The Efficacy and Safety of Clazakizumab, an Anti–Interleukin‐6 Monoclonal Antibody, in a Phase IIb Study of Adults With Active Psoriatic Arthritis

Philip J Mease, Jun Xing, Subhashis Banerjee, 2016, Arthritis & rheumatology.

Correction: Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial

Piet Geusens, Philip J Mease, Luminita Pricop, 2018, RMD Open.

2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria.

Philip J Mease, Daniel J Clauw, Frederick Wolfe, 2016, Seminars in arthritis and rheumatism.

Changes in Treatment Patterns in Patients with Psoriatic Arthritis Initiating Biologic and Nonbiologic Therapy in a Clinical Registry

Marc Mason, Philip J Mease, Mei Liu, 2017, The Journal of Rheumatology.

A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia.

Philip J Mease, L. Arnold, I. Russell, 2008, The Journal of rheumatology.